These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29911761)

  • 21. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
    Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
    N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy.
    Kang CI; Wi YM; Ko KS; Chung DR; Peck KR; Lee NY; Song JH
    Scand J Infect Dis; 2013 Jul; 45(7):519-25. PubMed ID: 23509913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Mortality risk factors for bloodstream infections caused by extended-spectrum beta-lactamase-producing microorganisms].
    Ferrández O; Grau S; Saballs P; Luque S; Terradas R; Salas E
    Rev Clin Esp; 2011 Mar; 211(3):119-26. PubMed ID: 21371702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India.
    Akram M; Shahid M; Khan AU
    Ann Clin Microbiol Antimicrob; 2007 Mar; 6():4. PubMed ID: 17378940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
    Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
    Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children.
    Fan NC; Chen HH; Chen CL; Ou LS; Lin TY; Tsai MH; Chiu CH
    J Microbiol Immunol Infect; 2014 Oct; 47(5):399-405. PubMed ID: 23834784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pediatric extended spectrum β-lactamase infection: Community-acquired infection and treatment options.
    Sethaphanich N; Santanirand P; Rattanasiri S; Techasaensiri C; Chaisavaneeyakorn S; Apiwattanakul N
    Pediatr Int; 2016 May; 58(5):338-46. PubMed ID: 26513341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Organisms causing community-acquired bloodstream infection in medical department: A single centre retrospective observational study.
    Suganthini R; Suvintheran T; Nor Zanariah ZA
    Med J Malaysia; 2024 Sep; 79(5):569-574. PubMed ID: 39352159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications, risk factors and mortality following community-onset bacteremia caused by extended-spectrum β-lactamase (ESBL) and non-ESBL producing Escherichia coli.
    Hsieh CJ; Shen YH; Hwang KP
    J Microbiol Immunol Infect; 2010 Jun; 43(3):240-8. PubMed ID: 21291853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Park SH; Choi SM; Chang YK; Lee DG; Cho SY; Lee HJ; Choi JH; Yoo JH
    J Antimicrob Chemother; 2014 Oct; 69(10):2848-56. PubMed ID: 24928854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of ertapenem, ciprofloxacin, ceftriaxone, piperacillin-tazobactam, and ampicillin-sulbactam against 12 common clinical isolates of community-acquired bacteremia.
    Hwang KP; Tang YF; Shen YH
    J Microbiol Immunol Infect; 2009 Oct; 42(5):433-8. PubMed ID: 20182674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clonal composition and community clustering of drug-susceptible and -resistant Escherichia coli isolates from bloodstream infections.
    Adams-Sapper S; Diep BA; Perdreau-Remington F; Riley LW
    Antimicrob Agents Chemother; 2013 Jan; 57(1):490-7. PubMed ID: 23147723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Worrisome high frequency of extended-spectrum beta-lactamase-producing Escherichia coli in community-acquired urinary tract infections: a case-control study.
    Castillo-Tokumori F; Irey-Salgado C; Málaga G
    Int J Infect Dis; 2017 Feb; 55():16-19. PubMed ID: 27979787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and Antimicrobial Resistance of Microbes Causing Bloodstream Infections in Unguja, Zanzibar.
    Onken A; Said AK; Jørstad M; Jenum PA; Blomberg B
    PLoS One; 2015; 10(12):e0145632. PubMed ID: 26700032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007.
    Al-Hasan MN; Lahr BD; Eckel-Passow JE; Baddour LM
    J Antimicrob Chemother; 2009 Jul; 64(1):169-74. PubMed ID: 19435736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing
    Park SY; Kang CI; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
    Korean J Intern Med; 2017 Jan; 32(1):146-157. PubMed ID: 27093979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of extended-spectrum β-lactamase-producing multidrug-resistant Escherichia coli among isolates from community-acquired infections and in silico structural modeling of an ESBL protein.
    Rajapandiyan K; Shanthi S; Vijayalakshmi P; Daisy P; Murugan M; Ranjitsingh AJ
    Microb Drug Resist; 2014 Apr; 20(2):170-6. PubMed ID: 24228708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
    Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.